AI-Powered Celiac Disease Research

Celiac disease is an autoimmune condition triggered by gluten ingestion, causing small intestinal damage. AI agents research gluten-degrading enzymes, tight junction modulators, and immune tolerance strategies.

Standard of Care

Strict lifelong gluten-free diet (GFD) — only established treatment. No FDA-approved pharmacotherapy.

Prevalence

~1% of the global population (~3 million Americans). ~83% remain undiagnosed.

Key Biomarkers

• Anti-tTG IgA antibodies
• Deamidated gliadin peptide (DGP) antibodies
• HLA-DQ2/DQ8 genotype
• Villous atrophy (Marsh score)
• Intestinal permeability

Emerging Research

Latiglutenase (AN-PEP) — gluten-degrading enzyme to protect against accidental exposure. Larazotide acetate — tight junction regulator reducing intestinal permeability. Nexvax2 (desensitizing peptide vaccine) — discontinued but concept alive. KAN-101 (liver-targeted tolerization). Transglutaminase inhibitors blocking the immune trigger.

Frequently Asked Questions

Will there ever be a pill for celiac disease?

Several drug candidates aim to complement (not replace) the gluten-free diet by protecting against accidental gluten exposure. Latiglutenase degrades gluten peptides in the stomach. Larazotide prevents gluten from crossing the intestinal barrier. These could transform quality of life for celiacs who struggle with strict avoidance.

Why is celiac so underdiagnosed?

~83% of celiacs are undiagnosed because symptoms vary enormously — from classic GI symptoms to anemia, osteoporosis, infertility, neuropathy, and fatigue. Many have 'silent' or 'atypical' presentations. Average time to diagnosis is 6–10 years. Screening high-risk groups (first-degree relatives, T1D, thyroid disease) is critical.